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Summary  The  prevalence  of  end-stage  renal  disease  has  increased  dramatically  in
developing  countries.  Hepatitis  B  virus  (HBV)  infection  is  a  global  health  problem  that
represents  a  signiﬁcant  co-morbidity  event  that  has  led  to  outbreaks  of  hepatitis  B.
There  are  inadequate  data  concerning  occult  HBV  infection  among  Egyptian  chronic
hemodialysis  patients.  This  study  aimed  to  detect  occult  HBV  infection  among
chronic  hemodialysis  patients  in  Alexandria,  Egypt.  A  cross-sectional  study  was  per-
formed  on  100  patients  with  end-stage  renal  disease  that  received  maintenance
hemodialysis  and  had  tested  negative  for  HBV  surface  antigen.  Blood  samples  were
collected  before  the  initiation  of  hemodialysis.  Sera  were  tested  for  hepatitis  C  virus
(HCV)  and  hepatitis  B  core  (HBc)  antibodies  using  ELISA,  and  HBV  DNA  was  detected
by  SYBR  Green  real-time  PCR  using  speciﬁc  primers  for  the  s  and  c  genes  and  by
nested  PCR  using  pol  gene-speciﬁc  primers.  The  serum  activity  of  alanine  and  aspar-
tate  aminotransferase  (ALT  and  AST)  were  also  measured.  Anti-HCV  and  anti-HBc
antibodies  were  detected  in  34%  and  48%  of  patients,  respectively,  and  70.6%  of  anti-
HCV  positive  patients  were  also  positive  for  anti-HBc  antibodies.  This  association  was
statistically  signiﬁcant  (p  = 0.001).  HBV  DNA  was  detected  in  32%  of  the  hemodialy-
sis  patients.  A  signiﬁcant  association  was  determined  between  the  presence  of  HBV
DNA  and  anti-HCV  positivity  (p  =  0.021).  Aminotransferases  were  elevated  in  21%  of
the  studied  patients,  more  often  in  patients  with  positive  anti-HCV  proﬁles  than  in
patients  negative  for  anti-HCV  (p  <  0.05).  In  conclusion,  the  serological  markers  of
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HBV  infection  should  be  veriﬁed  with  molecular  tests  to  investigate  possible  occult
ong  anti-HBc-positive  hemodialysis  patients,  to  improve  our
linical,  laboratory,  and  epidemiological  characteristics.
dulaziz  University  for  Health  Sciences.  Published  by  Elsevier
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patients are  assessed  every  three  months,  and  HBV-
positive patients  are  isolated  and  use  dedicated
dialysis machines.  Dialyzers  for  the  HBsAg-positiveinfections,  especially  am
understanding  of  their  c
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epatitis  B virus  (HBV)  infection  is  a  major  global
ealth  problem.  HBV  infection  can  have  different
linical presentations  that  range  from  a  carrier
tate to  cirrhosis  and  hepatocellular  carcinoma  [1].
ccording to  the  European  Association  for  the  Study
f the  Liver  (EASL),  approximately  one-third  of
he world’s  population  have  serological  evidence  of
ast or  present  hepatitis  B  virus  (HBV)  infection,
nd more  than  350  million  people  may  be  affected
y chronic  HBV  infection  [2].
Chronic HBV  infection  is  usually  diagnosed  when
irculating  hepatitis  B  surface  antigen  (HBsAg)  is
etected in  the  serum  in  the  presence  of  antibod-
es to  HBsAg  and/or  hepatitis  B  core  antibodies
anti-HBc).  However,  the  use  of  highly  sensitive
olecular biology  techniques,  such  as  polymerase
hain reaction  (PCR)-based  procedures,  permits  the
dentiﬁcation  of  HBV  DNA  in  HBsAg-negative  indi-
iduals, with  or  without  circulating  antibodies  to
BsAg and/or  hepatitis  B  core  antigen  [3].
Occult HBV  infection  is  characterized  by  the
resence of  HBV  DNA  in  the  liver  or  blood  even
hough HBsAg  is undetectable  in  the  serum  as  mea-
ured by  current  commercial  HBsAg  assays  [4].
he prevalence  of  occult  HBV  infection  is  variable
epending on  the  endemicity  of  the  disease  in  dif-
erent parts  of  the  world,  the  different  assays  used
nd the  different  populations  studied  [5].
The prevalence  of  occult  HBV  infection  in
emodialysis patients  in  a  North  American  popu-
ation was  reported  to  be  3.7%  [6]  compared  to
.9% in  India  [7]. In  Italy,  the  prevalence  ranged
rom 0%  in  a  cohort  of  213  dialysis  patients  [8]  to
6.6% in  another  cohort  [9],  while  in  Turkey,  preva-
ence  rates  up  to  12.4%  [10]  have  been  recorded.
 previous  study  carried  out  in  Egypt  reported
 prevalence  of  5.2%  occult  HBV  in  hemodialysis
atients [11].  As  can  be  inferred  from  these  reports,
he prevalence  of  occult  HBV  infection  in  hemodial-
sis patients  is  diverse,  and  the  factors  responsible
or this  variation  include  selection  bias,  the  sen-
itivity  and  speciﬁcity  of  the  tests,  health  care
easures  and  hemodialysis  machine  isolation  for
BV-positive  patients  [11].
a
w
pEnd-stage  renal  disease  (ESRD)  is  a  signiﬁcant
roblem in  nearly  all  countries,  and  the  prevalence
as increased  dramatically  in  developing  countries
12]. Although  the  prevalence  of  HBV  in  patients
ith ESRD  undergoing  dialysis  has  decreased  sig-
iﬁcantly  during  the  past  few  decades  [13],  it
emains a distinct  clinical  problem  due  to  the
mmunosuppressive  nature  of  renal  disease  that
ften leads  to  a  chronic  viral  infection  that  does
ot occur  in  immunocompetent  individuals.  HBV
nfection’s  major  clinical  importance  seems  to  be
fter renal  transplantation,  as  it  can  cause  reacti-
ation  episodes  that  may  be  severe  and  leading  to
atient’s death;  moreover,  dialysis  centers  present
n opportunity  for  pathogen  transmission  [14].
herefore, the  aim  of  this  study  was  to  investigate
he prevalence  of  occult  HBV  infection  in  patients
eceiving hemodialysis  at  a single  center  in  Alexan-
ria, Egypt.
ubjects and methods
 cross-sectional  study  was  carried  out  between
une and  September  2012.  One  hundred  patients
47 males  and  53  females  with  a  mean  age  of
7.8 ±  14.9  years  and  an  age  range  of  33  to  63
ears) with  end-stage  renal  disease  on  mainte-
ance hemodialysis  for  at  least  6 months’  duration
ere  included  in  this  study.  Subjects  for  the  study
ere selected  from  the  Hemodialysis  Unit  of  the
edical Research  Institute  of  Alexandria  University.
pproximately  130  patients  joined  the  maintenance
emodialysis program  of  our  unit  during  the  period
nder  review.  Each  patient  received  treatment  3
imes a week.  A  total  of  93%  of  the  tested  patients
equired a  blood  transfusion  at  some  point.  There
s a program  for  routine  analysis  for  HCV  anti-
odies, HBsAg  and  HIV  antibodies;  hemodialysisnd anti-HCV-positive  patients  were  separate  from
here the  HBsAg-negative  and  anti-HCV-negative
atients were  treated.
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Inclusion  criteria  included  end-stage  renal  dis-
ease on  regular  hemodialysis  (for  at  least  6  months’
duration).  Hepatitis  C  virus  (HCV)-infected  patients
were not  excluded  from  the  present  study.  Subjects
who presented  with  acute  or  chronic  HBV  infec-
tion as  marked  by  positive  HBs-Ag  or  with  other
causes of  liver  dysfunction  (e.g.,  primary  biliary
cirrhosis,  autoimmune  hepatitis,  continued  alcohol
abuse, and  HIV  infection)  were  excluded  from  the
present study.
Serum samples  were  collected  (before  initiation
of hemodialysis),  aliquoted,  and  stored  at  −80 ◦C.
The samples  were  tested  for  anti-HCV  antibod-
ies using  an  enzyme-linked  immunosorbent  assay
(ELISA)  (Abbott  Murex  Diagnostic  Division)  and  for
anti-HBc  using  a  commercially  available  anti-HBc
ELISA  kit  (DiaSorin,  Italy)  according  to  manufac-
turer’s instructions.  HBV  DNA  was  detected  by  SYBR
Green real-time  PCR  (Applied  Biosystems  Inc.,  Fos-
ter City,  CA,  USA)  using  speciﬁc  primers  for  the  s
and c genes  [15]  and  by  conventional  nested  PCR
using speciﬁc  primers  for  the  pol  genes  [16]. The
serum  aminotransferase  activity  [Alanine  amino-
transferase  (ALT)  and  aspartate  aminotransferase
(AST)] was  assessed  using  commercial  kits  (HUMAN,
Germany)  according  to  the  manufacturer’s  instruc-
tions.
Detection of HBV DNA
Detection  of  HBV  by  SYBR  Green  real-time  PCR
The assay  is  based  on  the  speciﬁc  ampliﬁcation
of HBV-DNA  using  primers  targeting  the  s  and
c-gened. For  surface  gene,  the  primers  used  were  s-
sense [5′-AGAACATCGCATCAGGACTC-3′ (159—178)]
and s-antisense  [5′-CATAGGTATCTTGCGAAAGC-3′
(642—623)].  For  the  core  gene,  the  primers
used were  c-sense  [5′-CTGGGAGGAGTTGGGGGA-3′
(1730—1747)]  and  c-antisense  [5′-GTAGAAGAATA-
AAGCCC-3′ (2503—2487)].  HBV  DNA  was  extracted
using a  QIAamp  DNA  mini  blood  kit  (Qiagen  Inc.,
Valencia, CA,  USA)  following  the  manufacturer’s
instructions.  The  ampliﬁcation  reaction  was  per-
formed  using  the  SYBR  Green  technique  and  speciﬁc
primers.  The  following  thermal  proﬁle  was  applied:
AmpliTaq  activation  at  95 ◦C  for  10  min,  followed
by 40  cycles  of  PCR  ampliﬁcation  including  denat-
uration  at  95 ◦C  for  15  s,  annealing  at  55 ◦C  for  30  s
and extension  at  72 ◦C  for  1  min.  A  melting  curve
analysis was  performed  to  determine  the  purity  and
speciﬁcity  of  the  ampliﬁcation  product.  The  melt-
ing curve  analysis  proﬁle  was  95 ◦C  for  1  min,  50 ◦C
for 30  s  and  95 ◦C  for  15  s.
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etection  of  HBV  DNA  (pol  gene)  by  nested  PCR
he HBpol  region  was  ampliﬁed  using  the  fol-
owing  primer  combinations  in  two  subsequent
CR reactions:  outer  sense  primer  HBPr134  (5′-
GCTGCTATGCCTCATCTTC-3′)  and  outer  antisense
rimer HBPr135  (5′-CA(G/A)AGACAAAAGAAAAT-
GG-3′). The  ampliﬁed  product  of  the  ﬁrst
ound PCR  was  targeted  by  nested  (inner)
rimers, including  the  sense  primer  HBPr75
5′-CAAGGTATGTTGCCCGTTTGTCC-3′)  and  the  anti-
ense primer  HBPr94  (5′-GG(T/C)A(A/T)AAAGGG-
CTCA(A/C)-GATG-3′).  The  thermocycling  proﬁle
onsisted  of  AmpliTaq  activation  at  95 ◦C  for
0 min,  followed  by  40  cycles  of  PCR  ampliﬁcation
sing the  following  temperatures:  denaturation
t 95 ◦C  for  30  s,  annealing  at 45 ◦C  for  30  s  and
xtension at  72 ◦C  for  30  s,  with  a ﬁnal  elongation
t 72 ◦C for  10  min.  The  thermal  proﬁle  of  the
ested reaction  contained  35  cycles  and  was
imilar to  the  outer  ampliﬁcation  proﬁle.  The
ested  ampliﬁcation  products  were  341  bp  long.
he products  were  analyzed  on  a 2%  agarose  gel
nd visualized  by  staining  with  ethidium  bromide.
tatistical analysis
tatistical  tests  were  performed  using  SPSS  soft-
are (version  16).  Data  were  analyzed  by  the
hi-square test.  A  p-value  of  less  than  0.05  was
onsidered  statistically  signiﬁcant.
esults
nti-HCV  and  anti-HBc  antibodies  were  detected  in
4% and  48%  of  the  studied  dialysis  patients,  respec-
ively. Serum  aminotransferases  (ALT,  AST)  were
levated  in  21%  of  patients  but  displayed  normal
ctivity  in  the  remaining  79%.  Of  the  anti-HCV-
ositive patients,  24/34  (70.6%)  were  also  positive
or anti-HBc  antibodies.  On  the  other  hand,  24/66
36.4%)  of  anti-HCV-negative  patients  were  posi-
ive for  anti-HBc  antibodies.  This  association  was
ound to  be  statistically  signiﬁcant  (2 =  10.531,
 =  0.001).  Table  1  illustrates  the  frequency  of  sur-
ace (s),  core  (c),  and  polymerase  (pol)  genes
mong anti-HBc-positive  dialysis  patients.  Occult
BV infection  was  detected  in  32  of  the  100
atients on  chronic  hemodialysis  therapy,  and  all
f these  patients  were  anti-HBc  positive.  HBV  DNA
as detected  using  the  SYBR  green  method  to
mplify the  s  gene  in  19/48  (39.6%)  patients,  while
he c  gene  could  be  detected  in  13/48  (27.1%)
atients. Conventional  PCR  ampliﬁed  the  pol  gene
Fig.  1] in  22/48  (45.8%)  of  the  anti-HBc-positive
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Table  1  Frequency  of  surface  (s),  core  (c),  and  poly-
merase  (pol)  genes  among  anti-HBc  positive  dialysis
patients.
HBV  gene  Anti-HBc  positive
dialysis  patients  (n  =  48)
No.  %
s  6  12.5
c  2  4.2
s,  c  2  4.2
pol  9  18.8
c,  pol 2 4.2
s,  pol 4 8.3
d
a
p
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Figure  1  Gel  electrophoresis  of  nested  PCR  of  pol  gene.
Lane  1:  DNA  ladder  (100  bp),  lane  2:  positive  control,  lane
3:  negative  control,  lanes  4—6:  positive  samples  (341  bp),
l
a
p
D
O
rS,  c,  pol 7  14.6
ialysis  patients.  HBV  DNA  was  not  detected  in
nti-HBc-negative  dialysis  patients.  Table  2  dis-
lays HBV  DNA  positivity  among  anti-HCV-positive
nd -negative  dialysis  patients.  A  signiﬁcant  asso-
iation was  found  between  the  presence  of  HBV
NA and  anti-HCV  positivity  (2p  =  5.369,  p  =  0.021).
able  3 shows  the  aminotransferases  (ALT,  AST)
ctivity  among  dialysis  patients  with  different  sero-
ogical proﬁle  for  anti-HCV  and  anti-HBc  antibodies.
t shows  that  a  signiﬁcantly  increased  number  of
atients  with  anti-HCV  positivity  also  have  elevated
minotransferases  levels  compared  to  those  with
A
t
t
Table  2  HBV  DNA  (s,  c  or  pol)  positivity  among  anti-HCV  p
HBV  DNA  Dialysis  patients  (n  =  100)
Anti-HCV  positive  
No.  %  
Positive  16  47.1  
Negative  18  52.9  
X2(p)  
Total  34  100  
2p: p value for Chi square test for comparing between the studied
* Statistically signiﬁcant at p ≤ 0.05.
Table  3  Aminotransferases  (ALT,  AST)  activity  among  dialys
and  anti-HBc  antibodies.
Aminotransferases  (ALT
and  AST)  activity
Serological  proﬁle
Anti-HCV  positive
anti-HBc  positive
n (%)
Anti-HCV  posi
anti-HBc  nega
n (%)
Normal  15  (62.5)  4  (40)  
Elevated  9  (37.5)  6  (60)  
Total  24  (100%)  10  (100%)  ane  7:  negative  sample.
nti-HCV-negative  proﬁle  and  a  positive  anti-HBc
roﬁle  (2 =  5.779,  p  = 0.016).
iscussion
ccult  HBV  infection  with  undetectable  HBsAg  is a
isk factor  for  hepatic  disease  development  [17].
mong the  hemodialysis  group,  regardless  of  loca-
ion, HBV  infection  is  a signiﬁcant  co-morbid  event
hat can  lead  to  outbreaks  of  hepatitis  B  [18,19]
ositive  and  negative  dialysis  patients.
Total
Anti-HCV  negative
No.  %
16  24.2  32
50  75.8  68
5.369* (0.021)
66  100  100
 group.
is  patients  with  different  serological  proﬁle  for  anti-HCV
Total
tive
tive
Anti-HCV
negative
anti-HBc  positive
n  (%)
Anti-HCV
negative
anti-HBc  negative
n (%)
22  (91.7)  38  (90.5)  79
2  (8.3)  4  (9.5)  21
24  (100%)  42  (100%)  100
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despite  the  implementation  of  multiple  measures
to reduce  new  infection  [8,13,20,21].
Several  factors  are  associated  with  the  increased
transmission of  HBV  among  hemodialysis  patients;
these  factors  include  using  the  same  machines  for
HBV infected  and  uninfected  patients,  the  presence
of undiagnosed  hepatitis  B  among  HBV  negative
groups and  the  preparation  of  injectable  medica-
tions in  the  dialysis  treatment  room  [21,22].
Broadly, in  the  present  work,  hemodialysis
patients  were  classiﬁed  upon  testing  for  hepati-
tis B  core  antibodies  as  being  seropositive  or
seronegative. Occult  HBV  infection  was  detected
in 32  of  the  100  patients  on  chronic  hemodialysis
therapy, and  all  of  these  patients  were  anti-HBc
positive. The  frequency  of  occult  infection  among
the hemodialysis  patients  studied  veriﬁes  previ-
ous ﬁndings  [23—26]. Although,  a  lower  prevalence
was reported  previously  [27], and  Goral  et  al.
[28]  reported  that  occult  HBV  was  absent  in  their
hemodialysis  patients.
The  prevalence  of  HBsAg  in  Egypt  is  of  interme-
diate endemicity  (2—8%).  However,  there  are  no
particular  estimates  of  the  prevalence  of  occult
HBV infection  in  different  population  groups  in
Egypt such  as  blood  donors,  patients  with  hemato-
logical malignancies,  and  patients  in  hemodialysis
studies. Exploring  the  occult  HBV  infection  preva-
lence  and  its  impact  on  different  population  groups
in Egypt  revealed  a  prevalence  ranging  from  4%
to 14%  among  blood  donors.  The  prevalence  of
occult HBV  infection  is  much  higher  in  patients
exposed to  multiple  blood  transfusions,  especially
when the  patient  is  immuno-compromised.  Occult
HBV infection  was  reported  in  21%  of  HCV-infected
Egyptian children  with  hematological  disorders  and
malignancies  with  liability  for  reactivation.  There
is preliminary  evidence  that  immuno-compromised
patients  are  more  susceptible  to  lower  infectious
doses and  are  at  a  higher  risk  of  developing  chronic
infections [29—32].
In Egypt,  previous  reports  from  studies  in  dial-
ysis units  have  indicated  that  the  prevalence  of
occult HBV  infection  ranges  from  4%  to  26%  among
patients [11,33—36]. These  discrepancies  in  the
frequencies  of  occult  HBV  infection  in  hemodial-
ysis patients  between  several  studies,  including
our study,  could  be  due  to  several  factors  such  as
geographic  location  [37], health  care  measures  in
hemodialysis  units,  differences  in  the  sensitivity
of the  methods  used  to  detect  the  viral  genome
[33,37],  and  the  size  of  the  study  groups  [38,39].
Occult HBV  is  thought  to  be  due  to  infection  with
mutant virus  that  cannot  be  detected  with  commer-
cially available  molecular  methods.  Such  mutations
could  result  in  impaired  antigen  production  by  the
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irus,  a reduced  rate  of  replication,  or  could  assist
iral persistence  [40].
Total anti-HBc  is  a marker  for  previous  contact
ith the  virus,  but  there  are  no  recommenda-
ions regarding  the  investigation  of  this  marker  in
emodialysis  units  [24].  The  present  study  demon-
trates the  importance  of  investigating  this  marker,
iven that  HBsAg-negative  hemodialysis  patients
ay nonetheless  carry  HBV  and  present  with  total
nti-HBc  positivity.  This  was  observed  in  the  present
tudy, as  forty-eight  patients  presented  with  the
otal anti-HBc  marker;  therefore  they  would  not
ave been  identiﬁed  routinely  in  the  hemodialy-
is units.  Thirty-two  (66.7%)  of  these  patients  were
ositive for  HBV  DNA.  Previous  studies  have  shown
hat, patients  who  are  positive  for  total  anti-HBc
ay present  occult  infection  [23,24,27].
Interference  with  HBV  by  other  viruses  is  one  of
he several  possibilities  that  have  been  hypothe-
ized as  the  mechanisms  of  occult  HBV  infection.
CV infection  is  strongly  associated  with  HBV  occult
nfection;  moreover,  it  has  been  shown  that  the
CV core  protein  is  able  to  inhibit  HBV  replica-
ion in  vitro  [41]. Patients  with  both  HBV  and
CV infections  may  show  a  large  spectrum  of  viro-
ogical proﬁles.  HCV  infection  can  suppress  HBV
eplication,  as  demonstrated  by  studies  showing
hat patients  with  chronic  hepatitis  B  who  are
o-infected with  HCV  have  lower  HBV-DNA  levels,
ecreased  activity  of  HBV-DNA  polymerase,  and
ecreased  expression  of  HBsAg  and  HBcAg  in  the
iver [42]. Moreover,  patients  with  chronic  HBV
nfection  who  become  superinfected  with  HCV  can
ndergo seroconversion  of  HBsAg.  This  effect  may
e mediated  by  the  host  immune  response  or  by  a
irect effect  of  HCV  proteins  [43].
In the  present  study,  anti-HCV  antibodies  were
etected in  34%  of  the  dialysis  patients.  The  obser-
ation that  70.6%  of  anti-HCV  positive  patients
ere also  positive  for  anti-HBc  antibodies  reﬂects
he signiﬁcant  association  between  the  presence  of
nti-HBc and  anti-HCV  antibodies  among  the  dial-
sis patients.  A  signiﬁcant  association  was  found
etween  the  presence  of  HBV  DNA  and  anti-HCV
ositivity. In  agreement  with  our  results,  studies  by
ilg et  al.  [44]  and  Helmy  et  al.  [45]  revealed  a
igh correlation  between  anti-HCV  and  hepatitis  B
ore antibodies.  Because  HBV  and  HCV  have  similar
ransmission  models,  co-infection  of  both  viruses  is
xpected to  be  common.
In  the  current  work,  small  number  of  cases
howed elevated  liver  transaminase  activity.
ncreased number  of  patients  with  anti-HCV  pos-
tivity showed  elevated  aminotransferase  levels
ompared  to  those  with  anti-HCV  negative  proﬁle.
his trend  was  independent  of  the  presence  of
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Rccult  hepatitis  B  virus  infection  among  chronic  he
nti-HBc  or  occult  HBV  infection.  The  long-lasting
ersistence of  the  virus  in  the  liver  may  provoke
 mild  but  continuous  inﬂammation  that  could
ave clinical  effects  in  cases  of  previous  liver
amage [46].  Because  serum  AST  and  ALT  levels
re commonly  used  as  screening  tests  for  liver
isease in  hemodialysis  patients,  recognition  of
iver damage  may  be  hindered  by  reduced  amino-
ransferase values  in  these  patients  as  liver  enzyme
bnormalities  tend  to  be  attenuated  in  dialysis
atients [11,23,27,47].
Aminotransferase  levels  in  the  ‘‘normal’’  range
or the  general  population  may  be  indicative  of
 pathologic  state  in  patients  receiving  dialysis.
onsequently, an  increase  in  the  baseline  levels
f these  enzymes  does  not  have  to  reach  the
‘high abnormal’’  range  to  indicate  the  presence
f HBV-related  liver  disease  [48], signifying  that  the
elationship  between  aminotransferase  activity  and
he degree  of  HBV-mediated  liver  damage  in  dialysis
atients  is  not  accurate.
This  study  helps  to  determine  the  current  sta-
us of  the  hepatitis  B  infection  and  the  prevalence
f the  occult  HBV  infection  in  dialysis  patients.
n important  question  related  to  these  ﬁndings  is
hether occult  HBV  infection  can  be  transmitted
o others  if  those  occult  carriers  were  dialyzed
y the  same  dialysis  equipment.  Consequently,
e could  not  exclude  nosocomial  transmission.
herefore,  detecting  such  patients  in  hemodial-
sis clinics  considered  to  be  an  important  issue
or avoiding  the  dissemination  of  the  virus  inside
hese  units.  Another  important  concern  is  that  the
xtent of  liver  disease  in  ESRD  patients  under-
oing hemodialysis  is  largely  unknown  and  thus
eeds  further  investigation,  especially  if  the  ESRD
s associated  with  chronic  HCV  infection.  Because
hey  have  similar  transmission  modes,  HBV  and
CV co-infection  is a  common  clinical  presentation.
onsequently,  preventing  viral  hepatitis  infection
s much  more  cost-effective  than  treatment.  Fur-
hermore,  follow-up  visits,  the  lack  of  which  is
onsidered  a  limitation  of  this  study,  together  with
he identiﬁcation  of  predictive  risk  factors  for
nfection and  molecular  epidemiology  to  deter-
ine if  patients  suffering  from  concurrent  liver
isease  that  experienced  long-term  adverse  clini-
al outcomes  are  essential  steps  to  identify  patients
equiring  therapeutic  intervention  and  to  prevent
pread  of  infection.
In conclusion,  investigating  total  anti-HBc  anti-
odies  among  dialysis  patients  could  identify
nrecognized occult  HBV  infections.  Serological
arkers are  commonly  used  to  identify  HBV  infec-
ion, but  these  should  always  be  backed  up
ith molecular  tests  to  detect  possible  occultialysis  patients  in  Alexandria,  Egypt  567
nfections.  Further  investigation  will  lead  to  a
etter understanding  of  the  clinical,  laboratory,
nd epidemiological  characteristics  of  occult  infec-
ions. Additional  multi-center  longitudinal  studies,
ncluding  larger  numbers  of  patients,  are  needed
o determine  the  impact  of  occult  hepatitis  B  in
he transmission  of  HBV  infection  in  hemodialysis
enters. Likewise,  further  studies  are  needed  to
valuate the  cost-effectiveness  of  including  PCR  to
etect pol  gene  of  hepatitis  B;  this  assay  demon-
trates  a  high  detection  rate  in  the  present  study,
nd its  implementation  could  improve  the  general
recautions  used  by  hemodialysis  units.
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